Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes

In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news